title: No association between neuropathy and restless legs in Parkinson's disease.
abstract: BACKGROUND
  The prevalence of restless legs syndrome (RLS) has been studied extensively in Parkinson's disease (PD), with conflicting findings. More recently, both neuropathy and leg motor restlessness (LMR) have been found to be significantly more prevalent in PD patients than in controls.
  
  
  OBJECTIVE
  Our objective was to determine whether RLS or LMR may be secondary to neuropathy, or its currently postulated determinants, cumulative levodopa usage and vitamin B(12) metabolism, in patients with PD.
  
  
  METHODS
  We compared prevalence of RLS, LMR and neuropathy in 37 PD patients and 37 age- and gender-matched controls. Correlations between RLS/LMR and neuropathy and symptomatic neuropathy, cumulative levodopa usage and vitamin B(12) levels were ascertained.
  
  
  RESULTS
  RLS prevalence was comparable in PD patients and controls (16.2% vs 10.8%; P = 0.30). LMR was significantly more common in PD patients than in controls (40.5% vs 16.2%; P = 0.038), as was neuropathy (37.8% vs 8.1%; P = 0.005). Neither RLS, nor LMR correlated with neuropathy or symptomatic neuropathy, cumulative levodopa exposure or serum vitamin B(12) levels in patients with PD. There was a non-significant trend for a correlation between LMR and earlier age of onset of PD (P = 0.069).
  
  
  CONCLUSIONS
  RLS and LMR appear unrelated to neuropathy or symptomatic neuropathy, cumulative levodopa usage, or serum vitamin B(12) levels in patients with PD. The occurrence of LMR may relate to the earlier onset of PD, raising the possibility of common pathophysiological mechanisms for PD and RLS, of which LMR may be an early manifestation in some patients.
authors.affiliation: Department of Neurology, University Hospitals of Leicester, Leicester, UK. yusuf.rajabally@uhl-tr.nhs.uk
authors.forename: Y A
authors.initials: YA
authors.lastname: Rajabally
authors.forename: J
authors.initials: J
authors.lastname: Martey
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D010300:Parkinson Disease / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000150:complications* / Q000453:epidemiology; D015995:Prevalence; D012148:Restless Legs Syndrome / Q000150:complications* / Q000453:epidemiology; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D014805:Vitamin B 12